Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups

Publication | Closed Access

DOI

Citations

References

2005

Year

Sergio Amadori, Stefan Suciu, Roberto Stasi, Roel Willemze, Franco Mandelli, Dominik Selleslag, Claudio Denzlinger, Petra Muus, Reinhard Stauder, Zwi Berneman,

Leukemia

Hematological MalignancyOncologyGemtuzumab OzogamicinMixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaPharmacologyClinical TrialsHematologyMyeloid NeoplasiaPharmacotherapyMedicineFrail Patients 61Health Sciences